Journal of Hypertension · 1991 · 12 citations · 0 references
MedicineCardiologyPharmacologyCardiovascular PharmacotherapyPharmacodynamicsRenal PathophysiologyBlood Pressure ControlBlood Pressure ManagementBlood Pressure RegulationHypertension ManagementHypertension PharmacotherapyRenal Blood FlowB-type Natriuretic PeptidesBeta-adrenergic AgentsBeta-adrenergic Blocker UseBlood PressureRenal Blood Flow MeasurementRenal Vascular ResistanceVascular ResistanceVolume Expansion Therapy
The hypotensive action of beta-adrenoreceptor blockers is not fully understood, there being a lack of studies focusing on possible relationships between beta-blockers and the secretion of atrial natriuretic peptide (ANP). In 10 patients with essential hypertension, we investigated the influence of betaxolol, a selective beta 1-adrenergic blocking agent, on renal function and on plasma levels of ANP during exercise, volume depletion and volume expansion. Chronic therapy with betaxolol (mean 14.5 mg/day) did not alter glomerular filtration rate and renal blood flow although blood pressure was reduced. Renal vascular resistance decreased from 12795 +/- 1064 dyn/s per cm5 to 10614 +/- 833 dyn/s per cm5 (P less than 0.005). Under betaxolol, basal ANP levels increased from 39 +/- 10 pg/ml to 80 +/- 19pg/ml (P less than 0.01). ANP increased during exercise and volume expansion but was decreased during volume depletion. ANP values observed under betaxolol treatment showed significantly higher values while preserving their dynamic features. We believe that the stimulating effect of betaxolol on ANP may at least partly account for its hypotensive action.